Journal of Clinical Oncology, Vol 15, 1492-1501, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9- aminocamptothecin in adult cancer patients

CH Takimoto, W Dahut, MT Marino, H Nakashima, MD Liang, N Harold, R Lieberman, SG Arbuck, RA Band, AP Chen, JM Hamilton, LR Cantilena, CJ Allegra and JL Grem
National Cancer Institute-Navy Medical Oncology Branch, Division of Clinical Sciences, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889-5105, USA. ctakim@helix.nih.gov

PURPOSE: To investigate the pharmacokinetics and pharmacodynamics of 9- aminocamptothecin (9-AC) infused over 72 hours at doses of 5 to 74 micrograms/m2/h. PATIENTS AND METHODS: 9-AC lactone and total (lactone plus carboxylate) plasma concentrations were measured in 44 patients with solid tumors using a high-performance liquid chromatography (HPLC) assay. Fifteen patients underwent extended pharmacokinetic sampling to determine the distribution and elimination kinetics of 9-AC. RESULTS: At steady-state, 8.7% +/- 4.7% (mean +/- SD) of the total drug circulated in plasma as the active 9-AC lactone. Clearance of 9-AC lactone was uniform (24.5 +/- 7.3 L/h/m2) over the entire dose range examined; however, total 9-AC clearance was nonlinear and increased at higher dose levels. In 15 patients treated at dose levels > or = 47 micrograms/m2/h, the volume of distribution at steady-state for 9-AC lactone was 195 +/- 114 L/m2 and for total 9-AC it was 23.6 +/- 10.6 L/m2. The elimination half-life was 4.47 +/- 0.53 hours for 9-AC lactone and 8.38 +/- 2.10 hours for total 9-AC. In pharmacodynamic studies, dose-limiting neutropenia correlated with steady-state lactone concentrations (Css) R2 = .77) and drug dose (R2 = .71). CONCLUSION: Plasma 9-AC concentrations rapidly declined to low levels following the end of a 72-hour infusion and the mean fraction of total 9-AC circulating in plasma as the active lactone was less than 10%. The pharmacokinetics of 9-AC may have a great impact on its clinical activity and should be considered in the design of future clinical trials of this topoisomerase I inhibitor.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Masubuchi, R. D. May, and R. Atsumi A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay Clin. Cancer Res., October 1, 2004; 10(19): 6722 - 6731. [Abstract] [Full Text] [PDF]

				H. Hochster, E. R. Plimack, C. D. Runowicz, J. Speyer, R. C. Wallach, J. Sorich, J. Mandeli, S. Wadler, J. Wright, and F. M. Muggia Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group J. Clin. Oncol., January 1, 2004; 22(1): 120 - 126. [Abstract] [Full Text] [PDF]

				J. A. Smith, R. A. Newman, F. H. Hausheer, and T. Madden Evaluation of In Vitro Drug Interactions with Karenitecin, a Novel, Highly Lipophilic Camptothecin Derivative in Phase II Clinical Development J. Clin. Pharmacol., September 1, 2003; 43(9): 1008 - 1014. [Abstract] [Full Text] [PDF]

				S. Sakuma, Z.-R. Lu, B. Pecharova, P. Kopeckova, and J. Kopecek N-(2-Hydroxypropyl)methacrylamide Copolymer-9-Aminocamptothecin Conjugate: Colon-Specific Drug Delivery in Rats Journal of Bioactive and Compatible Polymers, September 1, 2002; 17(5): 305 - 319. [Abstract] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				H. Minami, H. Fujii, T. Igarashi, K. Itoh, K. Tamanoi, T. Oguma, and Y. Sasaki Phase I and Pharmacological Study of a New Camptothecin Derivative, Exatecan Mesylate (DX-8951f), Infused Over 30 Minutes Every Three Weeks Clin. Cancer Res., October 1, 2001; 7(10): 3056 - 3064. [Abstract] [Full Text] [PDF]

				M.-L. Li, L. Horn, P. S. Firby, and M. J. Moore Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity Clin. Cancer Res., January 1, 2001; 7(1): 168 - 174. [Abstract] [Full Text]

				F. Hochberg, S. A. Grossman, T. Mikkelsen, M. Glantz, J. D. Fisher, S. Piantadosi, and the NABTT CNS Consortium Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma Neuro-oncol, January 1, 2000; 2(1): 29 - 33. [Abstract] [PDF]

				A. Sparreboom, M. J. A. de Jonge, C. J. A. Punt, W. J. Loos, K. Nooter, G. Stoter, M. G. Porro, and J. Verweij Prediction of the Systemic Exposure to Oral 9-Amino-20(S)-Camptothecin Using Single-Sample Analysis Drug Metab. Dispos., July 1, 1999; 27(7): 816 - 820. [Abstract] [Full Text]

				M. J.A. de Jonge, C. J.A. Punt, A. H. Gelderblom, W. J. Loos, V. van Beurden, A. S.Th. Planting, M. E.L. van der Burg, L. W.G.M. van Maanen, B. K. Dallaire, J. Verweij, et al. Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors J. Clin. Oncol., July 1, 1999; 17(7): 2219 - 2219. [Abstract] [Full Text] [PDF]

				V. M.M. Herben, R. van Gijn, J. H.M. Schellens, M. Schot, J. Lieverst, M. J.X. Hillebrand, N. E. Schoemaker, M. G. Porro, J. H. Beijnen, and W. W. ten Bokkel Huinink Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors J. Clin. Oncol., June 1, 1999; 17(6): 1906 - 1906. [Abstract] [Full Text] [PDF]

				H. Minami, T. E. Lad, M. K. Nicholas, E. E. Vokes, and M. J. Ratain Pharmacokinetics and Pharmacodynamics of 9-Aminocamptothecin Infused Over 72 Hours in Phase II Studies Clin. Cancer Res., June 1, 1999; 5(6): 1325 - 1330. [Abstract] [Full Text] [PDF]